AC Immune SA (ACIU) stock
Close on Nov 11, 2026Market cap $229.94MP/E –Yield –
AC Immune SA saw revenue fall 86.9% to CHF 3.57M over fiscal 2025. Free cash flow was -CHF 70.16M, down 207.5% from a year earlier. At the latest close the market valued the company at CHF 188.37M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- CHF 188.37M
- P/E ratio
- –
- Price to sales
- 52.72
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -37.25%
Fundamentals
- Revenue
- CHF 3.57M
- EPS, diluted
- -0.70 CHF
- Free cash flow
- -CHF 70.16M
Trading
- Previous close
- $2.29
- Open
- $2.32
- Day's range
- $2.23 – $2.33
- Volume
- 91,489
- Average volume (20 days)
- 208,308
- Beta (5 years)
- 1.19
- RSI (14 days)
- 46.0
- Volatility (1 year)
- 66.3%
- Relative volume
- 0.45×
- WACC
- 10.8%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACIU | S&P 500 | Difference | ACIU per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.6% | -2.4% | −7.2 pts | ||
| 3 months | -11.0% | -1.2% | −9.9 pts | ||
| Year to date | -28.0% | +12.3% | −40.3 pts | ||
| 1 year | -33.3% | +12.4% | −45.8 pts | ||
| 3 years | -22.1% | +78.8% | −100.9 pts | -8.0% | +21.4% |
| 5 years | -62.6% | +75.2% | −137.8 pts | -17.9% | +11.9% |
| 10 years | -85.0% | +311.1% | −396.1 pts | -17.3% | +15.2% |
Twelve years at a glance
Fiscal years 2014 to 2025, CHF
Revenue
Operating income
EPS, diluted
Free cash flow
Press releases
Releases AC Immune filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About AC Immune
Pharmaceutical Preparations
AC Immune SA is a clinical-stage biopharmaceutical company that discovers and develops precision therapeutics and diagnostic agents for neurodegenerative disorders, particularly Alzheimer’s disease and Parkinson’s disease. The company's pipeline comprises active immunotherapies, brain-penetrant small molecule inhibitors, monoclonal antibodies, and diagnostic positron emission tomography imaging tracers. These investigational candidates target misfolded pathological proteins, including amyloid beta, tau, alpha-synuclein, and TDP-43. AC Immune operates primarily through research, development, and licensing arrangements with major global pharmaceutical companies, which serve as commercialization partners alongside clinical trial participants.
Company profile, executives and historyAC Immune stock: common questions
What is AC Immune's stock price?
ACIU closed at $2.26 on Nov 11, 2026, down 1.31% on the day.
What is AC Immune's market cap?
AC Immune was worth $229.94M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ACIU's P/E ratio?
AC Immune lost money over fiscal 2025 (diluted EPS -0.70 CHF), so it has no meaningful P/E ratio.
How much revenue does AC Immune make?
AC Immune reported revenue of CHF 3.57M for fiscal 2025, down 86.9% from a year earlier.
Does AC Immune pay a dividend?
No. AC Immune has not paid a cash dividend over the last twelve months.
How has ACIU stock performed over the past year?
Including dividends, ACIU returned -33.3% over the past year, against +12.4% for the S&P 500.
Who are AC Immune's competitors?
Companies most similar to AC Immune by business, industry and size include COYA, ACRS, DNTH, IMNM, PRAX.
See a number that looks wrong?